ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis

Abstract Background Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10–50%) in metastatic, endocrine therapy-resistant cancers and are...

Full description

Bibliographic Details
Main Authors: Adi Zundelevich, Maya Dadiani, Smadar Kahana-Edwin, Amit Itay, Tal Sella, Moran Gadot, Karen Cesarkas, Sarit Farage-Barhom, Efrat Glick Saar, Eran Eyal, Nitzan Kol, Anya Pavlovski, Nora Balint-Lahat, Daniela Dick-Necula, Iris Barshack, Bella Kaufman, Einav Nili Gal-Yam
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Breast Cancer Research
Subjects:
Breast cancer
ESR1 mutation
Loco-regional/local recurrence
Metastasis
Endocrine treatment
Online Access:https://doi.org/10.1186/s13058-020-1246-5

Internet

https://doi.org/10.1186/s13058-020-1246-5

Similar Items